Medications for Neuroendocrine Tumors

8 results

  • detectnet

    (copper Cu 64 Dotatate)
    CURIUM US LLC
    Detectnet is indicated for use with positron emission tomography (PET) to localize somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.

  • everolimus

    (Everolimus)
    Natco Pharma Limited
    Everolimus is indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer, and for adult patients with progressive neuroendocrine tumors, renal cell carcinoma post sunitinib/sorafenib failure, renal angiomyolipoma in tuberous sclerosis, and subependymal giant cell astrocytoma in TSC.

  • ga-68-dotatoc

    (EDOTREOTIDE GALLIUM GA-68)
    UIHC – P E T Imaging Center
    Ga 68 DOTATOC Injection is indicated for use with PET to localize somatostatin receptor positive neuroendocrine tumors (NETs) in both adult and pediatric patients.

  • i 123 mibg

    (i 123 MIBG)
    AnazaoHealth Corporation
    Iobenguane (I-123 MIBG) is indicated for diagnostic imaging of adrenomedullary disorders, neuroendocrine tumors, pheochromocytomas, paragangliomas, neuroblastomas, carcinoid tumors, and medullary thyroid carcinoma. It assists in the evaluation, localization, and confirmation of these conditions, particularly when other tests yield unclear results.

  • kit for the preparation of indium in 111 pentetreotide

    (Indium In-111 Pentetreotide)
    Sun Pharmaceutical Industries, Inc.
    Indium In-111 pentetreotide injection is used for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors.

  • netspot

    (68Ga-DOTATATE)
    Advanced Accelerator Applications USA, Inc
    NETSPOT, after gallium-68 radiolabeling, is indicated for use with positron emission tomography (PET) to localize somatostatin receptor-positive neuroendocrine tumors (NETs) in both adult and pediatric patients.

  • octreoscan

    (Indium In -111 Pentetreotide)
    Curium US LLC
    Octreoscan is used for scintigraphic localization of primary and metastatic neuroendocrine tumors that express somatostatin receptors, following radiolabeling.

  • somatuline depot

    (lanreotide acetate)
    Ipsen Biopharmaceuticals, Inc.
    SOMATULINE DEPOT is indicated for long-term treatment of acromegaly, unresectable gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome in adults. It aims to normalize growth hormone levels, improve progression-free survival in GEP-NETs, and reduce the need for short-acting somatostatin analog rescue therapy in carcinoid syndrome.